Cash, Cash Equivalents, and Short-term Investments of Anixa Biosciences Inc from 31 Oct 2011 to 31 Jan 2026

Taxonomy & unit
us-gaap: USD
Description
Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.
Summary
Anixa Biosciences Inc quarterly Cash, Cash Equivalents, and Short-term Investments in USD history and change rate from 31 Oct 2011 to 31 Jan 2026.
  • Anixa Biosciences Inc Cash, Cash Equivalents, and Short-term Investments for the quarter ending 31 Jan 2026 was $14,202,000.
Source SEC data
View on sec.gov
Cash, Cash Equivalents, and Short-term Investments, Quarterly (USD)
Cash, Cash Equivalents, and Short-term Investments, YoY Quarterly Change (%)

Anixa Biosciences Inc Quarterly Cash, Cash Equivalents, and Short-term Investments (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $14,202,000 31 Jan 2026 10-Q 09 Mar 2026 2026 Q1
Q3 2025 $15,174,000 31 Oct 2025 10-Q 09 Mar 2026 2026 Q1
Q2 2024 $20,745,000 31 Jul 2024 10-Q 06 Sep 2024 2024 Q3
Q3 2023 $23,844,000 31 Oct 2023 10-Q 06 Sep 2024 2024 Q3
Q4 2018 $5,903,000 +$406,000 +7.4% 31 Jan 2019 10-Q 13 Mar 2019 2019 Q1
Q3 2018 $5,056,000 -$1,783,000 -26% 31 Oct 2018 10-Q 13 Mar 2019 2019 Q1
Q2 2018 $5,341,000 -$744,000 -12% 31 Jul 2018 10-Q 07 Sep 2018 2018 Q3
Q1 2018 $5,422,000 +$295,000 +5.8% 30 Apr 2018 10-Q 11 Jun 2018 2018 Q2
Q4 2017 $5,497,000 +$3,497,000 +175% 31 Jan 2018 10-Q 09 Mar 2018 2018 Q1
Q3 2017 $6,839,000 +$3,601,000 +111% 31 Oct 2017 10-K 11 Jan 2019 2018 FY
Q2 2017 $6,085,000 +$2,136,000 +54% 31 Jul 2017 10-Q 08 Sep 2017 2017 Q3
Q1 2017 $5,127,000 +$365,000 +7.7% 30 Apr 2017 10-Q 26 May 2017 2017 Q2
Q4 2016 $2,000,000 -$4,131,000 -67% 31 Jan 2017 10-Q 16 Mar 2017 2017 Q1
Q3 2016 $3,238,000 -$3,531,000 -52% 31 Oct 2016 10-K 09 Jan 2018 2017 FY
Q2 2016 $3,949,000 -$3,612,000 -48% 31 Jul 2016 10-Q 19 Aug 2016 2016 Q3
Q1 2016 $4,762,000 -$3,718,000 -44% 30 Apr 2016 10-Q 20 May 2016 2016 Q2
Q4 2015 $6,131,000 31 Jan 2016 10-Q 19 Feb 2016 2016 Q1
Q3 2015 $6,769,000 +$908,000 +15% 31 Oct 2015 10-K 08 Dec 2016 2016 FY
Q2 2015 $7,561,000 +$1,359,000 +22% 31 Jul 2015 10-Q 18 Aug 2015 2015 Q3
Q1 2015 $8,480,000 +$6,710,000 +379% 30 Apr 2015 10-Q 22 May 2015 2015 Q2
Q3 2014 $5,861,000 +$4,963,000 +553% 31 Oct 2014 10-K 23 Dec 2015 2015 FY
Q2 2014 $6,202,000 +$5,220,000 +532% 31 Jul 2014 10-Q 15 Sep 2014 2014 Q3
Q1 2014 $1,770,000 +$496,000 +39% 30 Apr 2014 10-Q 16 Jun 2014 2014 Q2
Q4 2013 $898,000 -$815,000 -48% 30 Nov 2013 10-Q 15 Sep 2014 2014 Q3
Q3 2013 $898,000 +$58,000 +6.9% 31 Oct 2013 10-K 29 Jan 2015 2014 FY
Q2 2013 $982,000 +$142,000 +17% 31 Jul 2013 10-Q/A 20 Sep 2013 2013 Q3
Q1 2013 $1,274,000 30 Apr 2013 10-Q/A 19 Jun 2013 2013 Q2
Q4 2012 $1,713,000 31 Jan 2013 10-Q/A 25 Mar 2013 2013 Q1
Q3 2012 $840,000 -$2,183,000 -72% 31 Oct 2012 10-K/A 17 Jan 2014 2013 FY
Q2 2012 $840,000 31 Jul 2012 10-Q/A 20 Sep 2013 2013 Q3
Q3 2011 $3,023,000 31 Oct 2011 10-K 29 Jan 2013 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.